Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

April 1, 2022

Study Completion Date

June 13, 2022

Conditions
Pediatric Central Nervous System Tumor
Interventions
DRUG

tozuleristide

Tozuleristide will be administered at least 1 hour and no more than 36 hours prior to planned surgical excision of their tumor.

DEVICE

Canvas System

All subjects enrolled in the study will have their tissue imaged with the Canvas System.

Trial Locations (9)

21287

Johns Hopkins University, Baltimore

32608

University of Florida Shands Hospital, Gainesville

38105

St. Jude Children's Research Hospital, Memphis

48201

Children's Hospital of Michigan, Detroit

55102

Children's Minnesota, Saint Paul

63110

Washington University St. Louis Children's Hospital, St Louis

90027

Chlidren's Hospital Los Angeles, Los Angeles

94158

University of California, San Francisco, San Francisco

98105

Seattle Children's Hospital, Seattle

Sponsors
All Listed Sponsors
collaborator

Pacific Pediatric Neuro-Oncology Consortium

OTHER

lead

Blaze Bioscience Inc.

INDUSTRY